Abstract: The present disclosure relates to psilocin compounds and pharmaceutically acceptable salts, polymorphs, stereoisomers, or solvates thereof, to pharmaceutical compositions, and in some embodiments, to serotonin 5-HT2 receptor agonists and uses in the treatment of diseases associated with a 5-HT2 receptor.

Abstract: In accordance with certain embodiments, lighting systems include one or more lightsheets each including a plurality of strings of light-emitting elements, control elements, and power conductors for supplying power to the light-emitting elements and control elements.

Abstract: The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor.

Abstract: The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor.

Abstract: The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor.

Abstract: Provided are methods for delivering psychedelic drugs to a patient in need thereof comprising administering via inhalation of a psychedelic drug in the form of an aerosol, methods for treating a central nervous system (CNS) disorder or psychological disorder via inhalation of a psychedelic drug in the form of an aerosol, devices for delivery of psychedelic drug and nitrous oxide mixtures by inhalation, including with remote activation and control, and methods for treating a central nervous system (CNS) disorder or psychological disorder via inhalation of nitrous oxide/oxygen mixtures having an amount of nitrous oxide of 15 to 25% by volume of total gas.

Abstract: There are disclosed deuterated 2C—X phenethylamine compounds, the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor, pharmaceutical compositions such as tablet compositions and kits containing the compounds, methods of delivering the compounds in a mist via inhalation, and methods of treating diseases or disorders associated with a serotonin 5-HT2 receptor, such as central nervous system (CNS) disorders or psychological disorders with the compounds of the invention.

Abstract: The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor.

Abstract: The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor.

Abstract: The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor.

Abstract: The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor.

Abstract: The present disclosure is directed to pharmaceutical compositions and to the use of such formulations in the treatment of diseases associated with a serotonin 5-HT2 receptor.

Abstract: The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor.

Abstract: The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor.

Abstract: The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor.

Abstract: The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor.

Abstract: Dual action compounds are provided that are inhibitors of catechol-omethyltransferase (COMT) enzyme and are also partial agonists or antagonists of the D2 receptor, or agonists of the D1 receptor, or interact in these ways with both D1 and D2 receptors. Use of the compounds for treating neuropsychiatric disorders, particularly schizophrenia and mild cognitive impairment, is also described.

Abstract: The present invention relates to screening methods and assays that are referred to herein as multi-parameter hight throughput screening (MPHTS) assays. These MPHTS assays are useful for identifying candidate pharmaceutical compounds. In particular, the screening methods of this invention may be used to identify compounds that have potential therapeutic benefits for the treatment of neuropscyhiatric and neurodegenerative disorders, including schizophrenia, bipolar affective disorder (BAD), autism and Alzheimer's disease to name a few.

Abstract: The present invention relates to screening methods and assays that are referred to herein as multi-parameter hight throughput screening (MPHTS) assays. These MPHTS assays are useful for identifying candidate pharmaceutical compounds. In particular, the screening methods of this invention may be used to identify compounds that have potential therapeutic benefits for the treatment of neuropscyhiatric and neurodegenerative disorders, including schizophrenia, bipolar affective disorder (BAD), autism and Alzheimer's disease to name a few.